Are there any potential therapeutic applications for targeting NEK7 in the treatment of inflammatory disorders?
Best insight from top research papers
Targeting NEK7 has potential therapeutic applications in the treatment of inflammatory disorders. NEK7 is involved in the activation of the NLRP3 inflammasome receptor, which plays a crucial role in regulating the innate immune system and inducing the maturation of inflammatory cytokines . The aberrant expression of NEK7 has been implicated in the growth of metastasis and severe inflammatory conditions such as rheumatoid arthritis, liver cirrhosis, and gout . In silico experiments and computational studies have identified several drugs, including Alectinib, Crizotinib, and compound 146476703, that can successfully inhibit the overexpression of NEK7 . Additionally, molecular dynamics simulations have shown the stability and dynamic characteristics of the NEK7-drug complexes, further supporting their potential as therapeutic agents . Furthermore, the virtual screening of benzene sulphonamide derivatives and the repurposing of FDA-approved drugs, such as Dacomitinib and Neratinib, have also demonstrated inhibitory efficacy against NEK7 . These findings suggest that targeting NEK7 could be a promising approach for the development of therapeutic interventions for inflammatory disorders.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The paper does not mention any potential therapeutic applications for targeting NEK7 in the treatment of inflammatory disorders. | |
| No, the paper does not mention any potential therapeutic applications for targeting NEK7 in the treatment of inflammatory disorders. The paper primarily focuses on the virtual screening of compounds for drug development against NEK7 in cancer malignancies. | |
2 Citations | The paper does not directly mention potential therapeutic applications for targeting NEK7 in the treatment of inflammatory disorders. |
| The paper suggests that targeting NEK7 could have potential therapeutic applications in the treatment of inflammatory disorders such as rheumatoid arthritis, liver cirrhosis, and gout. | |
| The paper does not mention any potential therapeutic applications for targeting NEK7 in the treatment of inflammatory disorders. |
Related Questions
Inflammasome as a therapeutic target?5 answersInflammasomes, particularly the NLRP3 inflammasome, are emerging as promising therapeutic targets in various diseases. These protein complexes play crucial roles in sensing danger signals, activating innate immunity, and promoting inflammation. In conditions like viral infections, dry eye disease, and COVID-19, targeting inflammasomes shows potential in modulating inflammatory responses and disease outcomes. For instance, suppressing NLRP3 inflammasome activation has shown promise in reducing mortality and morbidity in SARS-CoV-2-infected patients. In myopericardial diseases, inhibiting the NLRP3 inflammasome with agents like colchicine and anti-IL-1 drugs has demonstrated effectiveness in managing conditions like pericarditis and myocarditis. These findings highlight the therapeutic significance of targeting inflammasomes to mitigate inflammation-related pathologies and improve patient outcomes.
What are the therapeutic implications of targeting inflammation in cancer?5 answersTargeting inflammation in cancer has significant therapeutic implications. Chronic inflammation has been shown to promote tumor initiation and progression by causing DNA damage and activating oncogenic signaling pathways. Inflammatory cells and mediators within the tumor microenvironment also play a role in tumor progression and metastasis. Therefore, inhibiting inflammation can be a promising strategy for cancer prevention and therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) have shown potential in reducing the risk of carcinogenesis and improving the efficacy of existing anti-cancer treatments. Additionally, nanomedicine-based drug delivery approaches can enhance the therapeutic index of anti-cancer agents by selectively targeting tumor tissues and reducing systemic adverse effects. Furthermore, targeting inflammation in cancer treatment can offer a window of opportunity for combination therapies that increase the effectiveness of conventional cancer treatment modalities. Overall, targeting inflammation in cancer has the potential to improve outcomes and enhance the success of cancer prevention and therapy.
How can inflammatory agents be used to treat disease?4 answersInflammatory agents can be used to treat disease by targeting and reducing inflammation in the body. Chronic silent inflammation has been identified as a key feature in abdominal obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Pharmacological strategies that reduce inflammation have shown therapeutic potential in treating these conditions. Various approaches have been explored, including targeting specific molecules and pathways involved in inflammation. These include IKK-b-NF-kB, TNF-α, IL-1β, IL-6, AMP-activated protein kinase, sirtuin-1, mammalian target of rapamycin, and C-C motif chemokine receptor 2. Additionally, inhibiting CD 14 activity, TLR2 activity, and monocyte chemotaxis has also been investigated as a means to treat inflammatory diseases. Novel drug delivery systems, such as polymeric micelles, have been developed to improve the penetration of anti-inflammatory drugs through biological barriers and enhance their localization at targeted areas. These advancements in targeting inflammation offer potential therapeutic options for the treatment of various inflammatory diseases.
Is neurogenic inflammation a feasible therapeutic target in migraine, arthritis, asthma and fibromyalgia?3 answersNeurogenic inflammation is a feasible therapeutic target in migraine, arthritis, asthma, and fibromyalgia. In migraine, neuropeptides such as calcitonin gene-related peptide (CGRP), substance P (SP), and neurokinin A are involved in the pathophysiology, and medications that attenuate their release have shown efficacy. In arthritis, fibromyalgia, and asthma, there is evidence of neurogenically derived inflammatory mechanisms occurring in peripheral tissues, spinal cord, and brain, involving neuropeptides, chemokines, and cytokines. These inflammatory processes contribute to the clinical features of these conditions, such as pain, swelling, and fatigue. Targeting these inflammatory pathways may offer new therapeutic options for patients. For example, ongoing clinical studies are investigating monoclonal antibodies against CGRP and CGRP receptors for migraine treatment. However, further research is needed to fully understand the role of neurogenic inflammation in these disorders and to develop effective treatments.
Role of NF-Kb and netosis?5 answersNF-kB is a transcription factor that plays a crucial role in immune and inflammatory responses. It is involved in the activation of genes related to various diseases, including cardiovascular diseases, diabetes, and lymphoid malignancies. The activation of NF-kB is regulated by stimuli such as LPS, TNFα, and oxygen radicals. Neutrophil extracellular traps (NETs) are web-like structures released by activated neutrophils, and their formation, known as NETosis, is a form of cell death. NETs have been implicated in central nervous system (CNS) injury, including traumatic brain injury, cerebral ischemia, CNS infection, Alzheimer's disease, and spinal cord injury. The role of NETosis in CNS injury is still unknown, but it is considered a potential therapeutic target for the treatment of CNS injury. The cross-talk between NF-kB and NETosis pathways is not explicitly mentioned in the abstracts provided.
Is NF-kB regulate the expression of anti-inflammatory genes?2 answersNF-kB regulates the expression of anti-inflammatory genes. Betulin inhibits the gene expression of mucin through regulation of NF-kB signaling pathway in human airway epithelial cells. Astaxanthin has an anti-inflammatory effect and modulates the inflammatory response by reducing the expression of inflammation-related cytokines and chemokines through NF-kB signaling pathway. Pharmacological treatment with conventional drugs (CD) down-regulates TNFR signaling and pro-inflammatory mediators, while up-regulating anti-inflammatory factors including NF-kBIA and TNFAIP3 through negative regulation of NF-kB signaling in monocytes. Nigella sativa extract reduces the mRNA levels of NFk (p50, RelB) and IKK (IKKA, IKKB) in breast cancer cells, indicating an anti-inflammatory mechanism through inhibition of IKK/NF-kB activation pathway. NF-kB transcription factor plays a central role in controlling inflammation and immune homeostasis, and its subunits and regulators are involved in the regulation of inflammation-related diseases.